EP2126577A4 - Utilisation de he4 pour l'évaluation du cancer du sein - Google Patents

Utilisation de he4 pour l'évaluation du cancer du sein

Info

Publication number: EP2126577A4
Authority: EP; European Patent Office
Prior art keywords: breast cancer; assessing breast; assessing; cancer; breast
Prior art date: 2007-03-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP08727225A

Other languages

German (de)

English (en)

Other versions

EP2126577B1 (fr

EP2126577A1 (fr

Inventor

Jeffrey W Allard

Thorsten Verch

Curtis Glover

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fujirebio Diagnostics Inc

Original Assignee

Fujirebio Diagnostics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-29

Filing date

2008-03-31

Publication date

2010-06-02

2008-03-31 Application filed by Fujirebio Diagnostics Inc filed Critical Fujirebio Diagnostics Inc

2009-12-02 Publication of EP2126577A1 publication Critical patent/EP2126577A1/fr

2010-06-02 Publication of EP2126577A4 publication Critical patent/EP2126577A4/fr

2013-03-13 Application granted granted Critical

2013-03-13 Publication of EP2126577B1 publication Critical patent/EP2126577B1/fr

Status Active legal-status Critical Current

2028-03-31 Anticipated expiration legal-status Critical

Links

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)

EP08727225A 2007-03-29 2008-03-31 Utilisation de he4 pour l'évaluation du cancer du sein Active EP2126577B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US90884507P	2007-03-29	2007-03-29
PCT/US2008/004176 WO2008121391A2 (fr)	2007-03-29	2008-03-31	Utilisation de he4 pour l'évaluation du cancer du sein

Publications (3)

Publication Number	Publication Date
EP2126577A1 EP2126577A1 (fr)	2009-12-02
EP2126577A4 true EP2126577A4 (fr)	2010-06-02
EP2126577B1 EP2126577B1 (fr)	2013-03-13

Family

ID=39808837

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP08727225A Active EP2126577B1 (fr)	2007-03-29	2008-03-31	Utilisation de he4 pour l'évaluation du cancer du sein

Country Status (6)

Country	Link
US (1)	US8455189B2 (fr)
EP (1)	EP2126577B1 (fr)
JP (2)	JP5144742B2 (fr)
CA (1)	CA2682132C (fr)
ES (1)	ES2411921T3 (fr)
WO (1)	WO2008121391A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010061393A1 (fr) *	2008-11-30	2010-06-03	Compugen Ltd.	Séquences d'acides aminés et de nucléotides de variants de he4 et leurs procédés d'utilisation
US20130224772A1 (en) *	2010-08-26	2013-08-29	University Of Washington Through Its Center For Commercialization	Method for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells
JP5887364B2 (ja) *	2011-02-17	2016-03-16	フジレビオダイアグノスティックスインコーポレイテッド	ＨＥ４ａの測定のための組成物および使用方法
CN104655858B (zh) *	2015-03-12	2016-02-10	德迈基生物技术（北京）有限公司	定量检测人附睾分泌蛋白-4的荧光免疫层析试剂盒及其制备方法
KR20190107809A (ko)	2018-03-13	2019-09-23	한양대학교 산학협력단	자석을 포함하는 스퍼터링 장치

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002000677A1 (fr) *	2000-06-07	2002-01-03	Human Genome Sciences, Inc.	Acides nucleiques, proteines et anticorps
WO2003004989A2 (fr) *	2001-06-21	2003-01-16	Millennium Pharmaceuticals, Inc.	Compositions, trousses, et procedes d'identification, d'evaluation, de prevention, et de therapie pour le cancer du sein
WO2004063355A2 (fr) *	2003-01-10	2004-07-29	Protein Design Labs, Inc.	Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
WO2006135886A2 (fr) *	2005-06-13	2006-12-21	The Regents Of The University Of Michigan	Compositions et methodes pour le traitement et le diagnostic du cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5019513A (en) *	1985-06-04	1991-05-28	The Brigham And Women's Hospital, Inc.	Anti-bacterial T-cell factor
US5225539A (en) *	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
ATE243754T1 (de) *	1987-05-21	2003-07-15	Micromet Ag	Multifunktionelle proteine mit vorbestimmter zielsetzung
US5132405A (en) *	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5283173A (en) *	1990-01-24	1994-02-01	The Research Foundation Of State University Of New York	System to detect protein-protein interactions
US6783961B1 (en) *	1999-02-26	2004-08-31	Genset S.A.	Expressed sequence tags and encoded human proteins
US6770445B1 (en) *	1999-02-26	2004-08-03	Pacific Northwest Research Institute	Methods and compositions for diagnosing carcinomas
WO2002046765A2 (fr) *	2000-11-08	2002-06-13	Millennium Pharmaceuticals, Inc.	Compositions, trousses, et methodes d'identification, d'evaluation, de prevention et de traitement de cancers de l'ovaire
US7270960B2 (en) *	2001-08-29	2007-09-18	Pacific Northwest Research Institute	Diagnosis of ovarian carcinomas
US7666583B2 (en) *	2004-02-19	2010-02-23	Yale University	Identification of cancer protein biomarkers using proteomic techniques
CN101120252A (zh) *	2005-02-18	2008-02-06	儿童医疗中心有限公司	作为生物标记物用于上皮来源的癌症的诊断和预后的cyr61
CN101473041B (zh) *	2006-01-04	2017-11-14	富士瑞必欧美国公司	He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用

2008
- 2008-03-31 JP JP2010501021A patent/JP5144742B2/ja active Active
- 2008-03-31 WO PCT/US2008/004176 patent/WO2008121391A2/fr not_active Ceased
- 2008-03-31 EP EP08727225A patent/EP2126577B1/fr active Active
- 2008-03-31 CA CA2682132A patent/CA2682132C/fr active Active
- 2008-03-31 ES ES08727225T patent/ES2411921T3/es active Active
- 2008-03-31 US US12/593,625 patent/US8455189B2/en active Active
2012
- 2012-09-13 JP JP2012201690A patent/JP2013047679A/ja active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002000677A1 (fr) *	2000-06-07	2002-01-03	Human Genome Sciences, Inc.	Acides nucleiques, proteines et anticorps
WO2003004989A2 (fr) *	2001-06-21	2003-01-16	Millennium Pharmaceuticals, Inc.	Compositions, trousses, et procedes d'identification, d'evaluation, de prevention, et de therapie pour le cancer du sein
WO2004063355A2 (fr) *	2003-01-10	2004-07-29	Protein Design Labs, Inc.	Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
WO2006135886A2 (fr) *	2005-06-13	2006-12-21	The Regents Of The University Of Michigan	Compositions et methodes pour le traitement et le diagnostic du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GALGANO MARY T ET AL: "Comprehensive analysis of HE4 expression in normal and malignant human tissues", MODERN PATHOLOGY : AN OFFICIAL JOURNAL OF THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, INC JUN 2006,, vol. 19, no. 6, 1 June 2006 (2006-06-01), pages 847 - 853, XP002572898 *

Also Published As

Publication number	Publication date
CA2682132C (fr)	2022-03-22
HK1136630A1 (en)	2010-07-02
EP2126577B1 (fr)	2013-03-13
CA2682132A1 (fr)	2008-10-09
EP2126577A1 (fr)	2009-12-02
JP5144742B2 (ja)	2013-02-13
US8455189B2 (en)	2013-06-04
WO2008121391A2 (fr)	2008-10-09
JP2010522884A (ja)	2010-07-08
JP2013047679A (ja)	2013-03-07
ES2411921T3 (es)	2013-07-09
US20100311099A1 (en)	2010-12-09

Legal Events

Date	Code	Title	Description
2009-10-30	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2009-12-02	17P	Request for examination filed	Effective date: 20090930
2009-12-02	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2010-06-02	A4	Supplementary search report drawn up and despatched	Effective date: 20100504
2010-07-02	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1136630 Country of ref document: HK
2010-07-07	DAX	Request for extension of the european patent (deleted)
2011-05-04	17Q	First examination report despatched	Effective date: 20110401
2012-10-01	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2013-02-01	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2013-02-08	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2013-03-13	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2013-03-13	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2013-03-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 601100 Country of ref document: AT Kind code of ref document: T Effective date: 20130315
2013-04-10	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2013-05-08	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602008022877 Country of ref document: DE Effective date: 20130508
2013-05-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: RENTSCH PARTNER AG, CH
2013-07-09	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2411921 Country of ref document: ES Kind code of ref document: T3 Effective date: 20130709
2013-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130613 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130613 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313
2013-08-09	REG	Reference to a national code	Ref country code: HK Ref legal event code: GR Ref document number: 1136630 Country of ref document: HK
2013-08-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 601100 Country of ref document: AT Kind code of ref document: T Effective date: 20130313
2013-08-21	REG	Reference to a national code	Ref country code: NL Ref legal event code: VDEP Effective date: 20130313
2013-08-26	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2013-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130614
2013-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313
2013-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130713 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130715 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313
2013-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313
2014-01-01	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2014-01-17	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2014-01-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2014-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130331
2014-02-19	26N	No opposition filed	Effective date: 20131216
2014-03-27	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602008022877 Country of ref document: DE Effective date: 20131216
2014-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313
2015-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130313
2015-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080331
2016-03-02	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9
2017-03-10	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10
2017-09-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: BELLERIVESTRASSE 203 POSTFACH, 8034 ZUERICH (CH)
2018-03-08	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11
2023-06-14	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230510
2025-05-22	REG	Reference to a national code	Ref country code: DE Ref legal event code: R082 Ref document number: 602008022877 Country of ref document: DE
2025-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20250408 Year of fee payment: 18
2025-07-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20250416 Year of fee payment: 18
2025-11-28	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602008022877 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: G01N0033574000 Ipc: G01N0033575000
2026-04-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20260318 Year of fee payment: 19
2026-04-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MC Payment date: 20260325 Year of fee payment: 19
2026-04-10	REG	Reference to a national code	Ref country code: CH Ref legal event code: U11 Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260410
2026-04-13	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20260318 Year of fee payment: 19
2026-04-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LU Payment date: 20260325 Year of fee payment: 19 Ref country code: IT Payment date: 20260317 Year of fee payment: 19
2026-04-20	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20260325 Year of fee payment: 19

Publication	Publication Date	Title
FR23C1027I2 (fr)	2024-07-12	Régime de traitement à l'aide de nératinib pour le cancer du sein
EP2179317A4 (fr)	2012-11-07	Miniscope pour imagerie multidirectionnelle
EP2162552A4 (fr)	2010-06-30	Biomarqueurs pour mélanomes
EP1779289A4 (fr)	2012-01-25	Systeme de diagnostic pour mammographie multimodale
EP2082065A4 (fr)	2011-01-05	Test pronostique multigénique pour le cancer du poumon
FR2907222B1 (fr)	2015-04-10	Systeme d'inspection mobile pour vehicules
EP2048931A4 (fr)	2010-11-03	Attelage à trois points pour véhicule utilitaire
EP2310585A4 (fr)	2014-07-09	Systeme d'ecoulement pour bidets
GB0712303D0 (en)	2007-08-01	New use for cannabinoid
FR2917714B1 (fr)	2009-11-27	Turboreacteur pour aeronef
FR2880800B3 (fr)	2007-11-02	Teterelle pour meres allaitantes
EP2119428A4 (fr)	2013-03-06	Agent pour améliorer les ondulations de la chevelure
FR2919475B1 (fr)	2012-09-21	Pantalon transformable pour femme
EP1901733A4 (fr)	2011-06-15	Utilisation d'huperzine pour des pathologies
EP2596347A4 (fr)	2016-03-30	Laboratoire-sur-puce pour une analyse d'alcalinité
FR2873282B1 (fr)	2007-04-13	Trocart pour biopsie osteo-medulaire
EP2176651A4 (fr)	2013-02-20	Bandes d'essai électrochimiques
EP2126577A4 (fr)	2010-06-02	Utilisation de he4 pour l'évaluation du cancer du sein
FR2916604B1 (fr)	2009-09-04	Structure porteuse pour retourneuse d'andains
EP1888787A4 (fr)	2010-03-24	Utilisation du profilage de l'expression génique pour prédire la survie d'un patient atteint de cancer
EP2580287A4 (fr)	2015-05-20	Agent anticratère pour composition d'électrodéposition
EP1907857A4 (fr)	2009-08-05	Biomarqueurs du cancer du sein
EP2080744A4 (fr)	2010-03-24	Réactif pour trifluorométhylation
EP2210099A4 (fr)	2011-03-16	Biomarqueurs pour cancer des ovaires
EP2649225A4 (fr)	2015-06-10	Biomarqueurs pour la prédiction du cancer du sein